Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aspen Global Incorporated

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

- PMLiVE

AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer

Approximately 210,000 people worldwide are diagnosed with the disease every year

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval for paediatric patients with severe asthma

Severe eosinophilic asthma causes inflammation in the lungs and airways of patients

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi in small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer cases

- PMLiVE

AstraZeneca’s Voydeya granted FDA approval for rare blood disease PNH

Up to 20% of patients treated with C5 inhibitors experience clinically significant extravascular haemolysis

- PMLiVE

AstraZeneca’s Ultomiris receives FDA approval to treat rare autoimmune disease NMOSD

Neuromyelitis optica spectrum disorder is estimated to affect approximately 6,000 adults in the US

- PMLiVE

AstraZeneca’s Tagrisso combination shows promising overall survival trend in phase 3 lung cancer study

An estimated 2.4 million people globally are diagnosed with lung cancer every year

- PMLiVE

AstraZeneca to acquire Fusion Pharmaceuticals in deal worth $2.4bn

The transaction includes a potential new treatment for metastatic castration-resistant prostate cancer

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

- PMLiVE

AstraZeneca expands rare disease pipeline with $1.05bn Amolyt Pharma acquisition

The deal gives the company access to a late-stage candidate being evaluated for hypoparathyroidism

- PMLiVE

AstraZeneca announces plans to invest £650m in UK to boost life sciences sector

The investment will also help to enhance public health protection and pandemic preparedness in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links